Compare OZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | LUNG |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 57.9M |
| IPO Year | 2020 | 2020 |
| Metric | OZ | LUNG |
|---|---|---|
| Price | $46.61 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 6.2K | ★ 393.9K |
| Earning Date | 05-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | N/A | ★ N/A |
| Revenue | $9,187,000.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 243.44 | 8.01 |
| 52 Week Low | $47.00 | $1.13 |
| 52 Week High | $69.00 | $3.88 |
| Indicator | OZ | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 53.50 |
| Support Level | N/A | $1.36 |
| Resistance Level | $51.50 | $1.64 |
| Average True Range (ATR) | 0.80 | 0.12 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 0.00 | 57.78 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.